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RESEARCH ARTICLE Open Access
Healthcare reimbursement costs of children
with type 1 diabetes in the Netherlands, a
observational nationwide study (Young
Dudes-4)
E. A. J. M. Spaans1,2* , P. R. van Dijk1,3,4, K. H. Groenier1,5, P. L. P. Brand2,7, N. Kleefstra1,6 and H. J. G. Bilo1,4,5
Abstract
Background: Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases in children. Studies on
costs related to T1DM are scarce and focused primarily on the costs directly related to diabetes. We aimed to
investigate both the overall healthcare costs and the more specific costs related to the management of diabetes.
Methods: This is a retrospective and observational, nationwide cohort study of all Dutch children (aged 0–18 years)
with T1DM. Data were collected from the national registry for healthcare reimbursement, in which all Dutch
insurance companies combine their reimbursement data. In the Netherlands for all Dutch citizens health care is
covered by law and all children are treated by hospital-based paediatricians.
Results: We analysed 6710 children distributed over 81 hospitals: 475 children in 6 university hospitals and 6235
children in 75 general hospitals. Total reimbursement for all children with T1DM over the period 2009 to 2011 was
€ 167,494,732 corresponding to an annual mean of € 55,831,577 of total costs and € 8326 euros per child. When
comparing small (between 26 and 54 patients), medium (57–84 patients) and large (88–248 patients) general
hospitals, costs per patient were highest in the hospitals with the highest number of T1DM patients. The costs for
devices, secondary care and pharmaceutics had most impact on total expenditures. Over the study period, there
was a slight decrease in per person costs.
Conclusion: The overall health expenditure of a child with T1DM is more than € 8000 per patient per annum.
Given the move towards more device-intensive multidisciplinary care for these patients, the costs of treating T1DM
in children are likely to increase further in the coming years.
Keywords: Diabetes mellitus, Hospital admission, Children, Reimbursement costs, Nationwide
Background
Type 1 diabetes mellitus (T1DM) is one of the most com-
mon chronic diseases in children in developed nations [1].
The incidence rate of T1DM in the Netherlands has dou-
bled over the past three decades to 21 per 100,000 chil-
dren aged 14 years and younger [2]. The management of
T1DM is intensive and complex. During the past decades,
T1DM management has evolved from a physician-patient
relation using ‘one-size fits all’ multiple daily injection
insulin therapy to a multidisciplinary team approach with
new insulin preparations, insulin pump therapy, and (con-
tinuous) glucose sensors. It is likely that this move to-
wards more complex, intensive and multidisciplinary care
raises the costs of treatment per child. Together with the
increase in prevalence rates of T1DM in children this will
have considerable impact on the budget needed to deliver
appropriate care for these patients. More insight in such
changes allows for better planning and a more solid cor-
roboration of the needed funds.
There are currently only a few studies reporting the
costs of T1DM among children [3–6]. An increase in
the costs over the last decades was observed by most of
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these studies [4, 7]. These studies reported that hospital
(re-)admissions, devices and medication are the bulk of
healthcare expenses. There is also an indication that
the number of re-admissions is lower in larger hospitals
[8]. However, most of these reports were of a
cross-sectional nature. Furthermore and importantly, as
these studies only reported the costs directly related to
diabetes, the overall healthcare costs for children with
T1DM remain unknown. When assessing information
with regard to total health care expenditure for adult
persons with diabetes, data suggest that more expend-
iture is needed for general care not directly related to
diabetes compared to diabetes related care [9]. To our
knowledge, a comparable analysis has not been per-
formed in children with T1DM.
The aim of the present study was to investigate both
the overall and diabetes-specific healthcare costs as de-
rived from reimbursement data related to the manage-
ment of Dutch children with T1DM aged 0 to 18 years.
In order to gain more insight in the various aspects of
costs, we also investigated its course, determinants and
differences according to size of hospitals.
Methods
Study design
Retrospective, observational, nationwide study in the
Netherlands study covering a period of 3 years (2009 to
2011). This study is part of the Young DUtch Diabetes
Estimates (DUDE) initiative, a nation-wide project aimed
at investigating the magnitude and impact of diabetes mel-
litus, complications and costs among children and adoles-
cents in the Netherlands [2]. Aim of the present analysis
was to investigate the overall and diabetes-specific health-
care costs related to the management of Dutch children
(aged 0 to 18 years) with T1DM.
Outcomes
Primary outcome measure was the annual total health-
care costs related to children with T1DM (aged 0 to
18 years) in the period 2009 to 2011 in the Netherlands.
As a secondary outcome measure we divided the costs
according to nature (pharmaceuticals, device related, pri-
mary and secondary care consultations, admissions, ma-
ternity care, dental health and mental health). We also
analysed the following putative determinants of costs:
hospital type (university hospitals and general hospitals
divided into tertiles according to the number of T1DM
patients cared for in the hospital; hospitals caring for
less than 20 children with T1DM were excluded from
analysis) and number of readmissions.
The available data on reimbursed health care expend-
iture were not corrected for Consumer Price Index (CPI)
changes. CPI changes are known for the Netherlands, be-
ing 1.3% for 2010 vs 2009, and 2.3% for 2011 vs 2010.
However, in the Netherlands, not all expenditure is in-
cluded in the calculation of the CPI: income tax, social
premiums and spending on insured health care, for ex-
ample, are nor taken into account (https://www.cbs.nl/
en-gb/background/2005/26/consumer-price-index). There-
fore, correcting for the CPI would not add to a better un-
derstanding of the available information.
Data collection
Throughout the 3-year study period, reimbursement of
all hospital care was handled through the registration as
Diagnosis Treatment Combination (Diagnose-Behandel
Combinatie (DBC) in Dutch) codes. All Dutch children
with T1DM are treated by hospital-based paediatricians
and these physicians are required to record information
by the appropriate DBC codes [2]. Importantly, each
DBC code contains information about the attending
physician (e.g. the specific specialty), the diagnosis, and
the type of care provided. All DBC codes are stored in a
national database, managed by Vektis (Vektis, Zeist, The
Netherlands; https://www.vektis.nl/). Besides this data-
base Vektis also manages other databases including the
Basic Health Insurance Information System. This data-
base contains demographic information (e.g. date of
birth and gender) and information on drug prescription,
for all children that are registered as inhabitants in the
Netherlands. The coverage of this system is approxi-
mately 98% [10]. Claims records for pharmaceutical care,
with a coverage of 99%, were derived from the Pharmacy
Information System, containing information on the date
the drug was supplied, the physician prescribing the
drug, the specific drug that was supplied (including
Anatomical Therapeutic Chemical (ATC) code), and the
quantity supplied. Since all healthcare system records,
including the Pharmacy Information System, use the same
unique identifying number for each patient (the ‘Citizen
Service Number’), we were able to link all claims for any
individual together and thereby track each individual
through all domains of healthcare and over time [11].
Resource costs were derived from the BASIC Detail
Information database. This database provides insight
into the total reimbursement of declared DBCs and
other items as described below, under the Health Insur-
ance Act (which then can be seen as a rather accurate
proxy of costs of care), classified by type of healthcare
procedure and aggregated into specific cost categories.
The specific categories are: primary care, medications,
dental care, obstetric care, paramedical assistance (in-
cluding physiotherapy, speech therapy practice, dietet-
ics), devices, patient transport and travel related costs,
maternity care, mental health, and secondary care.
Coverage of the BASIC Detail Information database is
approximately 100%. Data available for research pur-
poses were stripped from identifying characteristics to
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ensure anonymity: the Citizen Service Number was
encrypted, date of birth converted into the person’s age,
and the postal code recoded to limit its identifying
properties to hospital level. All hospitals were num-
bered to avoid direct recognition of specific hospitals.
We extracted data about overall health care expend-
iture and more detailed in accordance with the above
named subdivision.
Patients
We selected children aged 18 years or younger on the
1st of July for every single year of the study period
(2009–2011). In this group, children with at least one
DBC claim for diabetes mellitus (paediatrics code [0316]
and diabetes diagnosis code [7104], or internal medicine
code [0313] and diabetes diagnosis code [221, 222 or
223]) were included.
Statistical analysis and ethical considerations
Statistical analyses were carried out using SPSS (IBM
SPSS Statistics for Windows, Version 20.0. Armonk, NY:
IBM Corp.). All costs are expressed in Euros (€). As
retrospective studies using anonymized data are exempt
from ethical review under Dutch law, medical ethics ap-
proval was not required for this study. This was con-
firmed in writing by the ethical review board of Isala
hospital.
Results
A total of 91 hospitals (8 university and 83 general hos-
pitals) were included. Two university hospitals and 8
general hospitals were excluded because they cared for
less than 20 children with T1DM each. The study sam-
ple comprised 6710 children whose T1DM was managed
at 81 hospitals: 475 children in 6 university hospitals and
6235 children in 75 general hospitals. The number of
children per year is presented in Table 1.
The total reimbursement for all children with
T1DM over the period 2009 to 2011 was €
167,494,732 (Table 1), corresponding to a mean of €
8326 per child per year. Mean costs were € 8326 per
child when children were seen in general hospitals for
Table 1 Costs (in euros) for management of type 1 diabetes in the period 2009 to 2011 in the Netherlands
2009 2010 2011 Total Mean
General hospitals
Total 52,936,879 53,273,011 49,431,443 155,641,333 51,880,444
Mean 8639 8570 7769 24,977 8326
Number of children 6128 6216 6363 18,707 6236
Large
Total 33,420,336 33,039,872 31,393,730 97,853,938 32,617,979
Mean 9382 9087 8277 26,746 8915
Number of children 3562 3636 3793 10,991 3664
Medium
Total 11,917,983 12,481,770 11,491,543 35,891,295 11,963,765
Mean 7496 7681 7107 22,283 7428
Number of children 1590 1625 1617 4832 1611
Small
Total 7,598,559 7,751,370 6,546,171 21,896,100 7,298,700
Mean 7785 8117 6869 22,771 7590
Number of children 976 955 953 2884 961
University hospital
Total 3,953,900 4,113,517 3,785,982 11,853,399 3,951,133
Mean 8036 9223 7790 25,050 8350
Number of children 492 446 486 1424 475
Total
Total 56,890,779 57,386,528 53,217,426 167,494,732 55,831,577
Mean 8594 8614 7770 24,978 8326
Number of children 6620 6662 6849 20,131 6710
Costs are subdivided according to type and volume of hospital; and are presented as total costs (upper row) and mean costs per child (middle row). The total
number of children is presented in the lower row
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their T1DM, and € 8350 when children were seen in
a university hospital. Costs for devices, medical spe-
cialist consultations and pharmaceutics had most im-
pact on the total expenditures (Table 2). Over the
study period, there was a decrease in costs, both for
general and university hospitals. In general, the costs
for general practitioners and paramedical care in-
creased while costs for mental health, dental health
and secondary care decreased.
In Fig. 1, The mean costs (in euros) per child accord-
ing to the number of patients per hospital and the aver-
age annual costs (in euros) per child with T1DM are
shown when comparing hospitals, caring for different
numbers of patients. Costs were highest in hospitals
with the largest number of patients (Table 1 and Fig. 1).
Discussion
This study found that the mean costs of treating T1DM
(based on reimbursement data) in children in the
Netherlands are € 8326 per child. Healthcare costs asso-
ciated with children proved to be higher when children
were being treated for their diabetes in a larger general
hospital, with more or less the same health care expend-
iture per child as in an university hospital.
The costs of treating a child with T1DM in this study
are considerably higher than those reported earlier. In
Europe, previous studies from Germany (2007) and
Greece (2011 to 2012) reported mean annual costs per
child with T1DM of € 3542 and € 2712, respectively [4,
12]. The Greek study included only 89 children [12]. A
study from California (2009 to 2012) reported median me-
dian annual costs of US$ 7654 (€ 6850 euros) [13],
and a small Brazilian study (2008 to 2010) [14],
which did not include hospital admissions, reported
average annual costs of $ 1319 (€ 1180). Differences
in organization and accessibility of health care and
standards of diabetes care hamper the comparison of
such costs between countries.
Our study is the first to incorporate all costs (includ-
ing e.g. paramedical and dental care) for children with
T1DM. Previous studies only examined costs for drugs,
devices or hospital admissions directly associated with
diabetes [4, 12, 14]. In addition, differences in the use of
devices such as insulin pumps, may have influenced the
differences between countries [4, 13, 14]. Apart from
hospitalization, the use of such devices is the main de-
terminant of costs for diabetes. The few studies report-
ing both costs and insulin pump usage showed marked
differences in the proportion of T1DM patients using in-
sulin pumps, ranging from 1.2% in Brazil (2008 to 2010)
[14], 18% in California (July 1st 2009 to June 30th 2012)
[13] to more than 25% in Germany 2007 [8] and 37% in
the Netherlands (unpublished data). In addition, studies
differ in the proportion of medical costs spent on phar-
maceuticals, ranging from 12 to 33%, indicating that dif-
ferences in the costs of insulin may also influence the
results [5, 14]. There are also methodological differences
between studies, the different population profiles ana-
lyzed and the differences between the unit costs of
health services between countries hampering mutual
comparison. There also seems to be a relationship be-
tween higher costs and poorer metabolic control which
is related to increased admissions in children and
Table 2 Determinants of the costs (in euros) for management of
type 1 diabetes in the period 2009 to 2011 in the Netherlands
2009 2010 2011 Mean
Dental health
Total 847,398 919,940 824,414 863,917
Mean 128 138 120 129
Device-related costs
Total 22,169,761 22,806,472 22,383,567 22,453,267
Mean 3349 3423 3268 3347
First-line care
Total 780,656 753,617 852,229 795,500
Mean 59 57 62 59
Maternitiy care
Total 5500 2008 2402 3304
Mean 0 0 0 0
Secundary care
Total 22,495,905 21,743,263 18,468,504 20,902,557
Mean 3398 3264 2697 3119
Mental health
Total 3,232,896 3,482,130 2,777,693 3,164,239
Mean 488 523 406 472
Other costs
Total 417,630 409,597 391,223 406,150
Mean 32 31 29 30
Paramedical care
Total 419,264 486,974 532,576 479,605
Mean 63 73 78 71
Travel related costs
Total 69,142 67,299 70,042 68.828
Mean 10 10 10 10
Pharmaceuticals
Total 6,452,628 6,715,226 6,914,777 6,694,210
Mean 975 1008 1010 997
Total
Total 56,890,779 57,386,528 53,217,426 55,831,577
Mean 8594 8614 7770 8326
Costs are presented as total costs (upper row) and mean costs per child
(lower row)
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intensive care [4–6, 8, 15], and a lower socioeconomic
status is correlated with higher costs partly as result of a
higher admissions rate [8, 16–18]. On the other hand,
patients with the poorest control tended to have rela-
tively lower costs for supplies, outpatient visits and la-
boratory tests but higher hospitalization costs [12].
In the present study, the average annual costs of treat-
ing T1DM in children was higher in hospitals caring for
more patients (Fig. 1). This is surprising as it is com-
monly believed that a larger patient volume would allow
for lower per person overhead costs, and – thus – to
lower overall costs per individual patient. Furthermore,
out-of-office hours services are probably better devel-
oped in larger institutes. In large centres, the availability
of a dedicated 24-h service might allow resolving dia-
betes specific problems without need for admission. The
finding that the number of admissions of children with
T1DM is lower in larger centers supports this hypothesis
[8, 18]. On the other hand it is likely that larger centers
treat more complex cases. Also, other factors such as
socio-economic status could be of influence (19).
Further studies are needed to identify the factors respon-
sible for the higher costs in larger hospitals. Finally, it
should be mentioned that we investigated the sum of all
large, medium and small centres and there could be in-
dividual centres with lower costs than expected.
Because of the rapid developments in the innovation
of the treatment of T1DM [19–22] with an increasing
use of high-tech devices, the costs of treating T1DM in
children are likely to increase further in the coming
years. Data from adults with diabetes suggest that more
expenditure is needed for general care not directly re-
lated to diabetes compared to diabetes related care [9].
The present study provides insight in the total health care
expenditure and specific diabetes-related costs of T1DM
care among children in the Netherlands. Hopefully, the
insight gained will allow a better understanding and plan-
ning of health care needs of this selected population, not
only with respect to diabetes, but also in general. The
main strength of our study is that we provide a nationwide
perspective of all the costs associated with the manage-
ment of children with T1DM, including dental and mental
health. The following limitations should be mentioned.
First, we did not examine the influence of patient charac-
teristics on costs. Previous studies found that the cost of
girls are higher than for boys [4, 8, 18] and this may by
quite different per age category [4, 5, 8]. Second, we were
unable to specify the different aspects of the costs on a
more detailed level due to the structure of the DBC sys-
tem in the Netherlands. Finally, the cross-sectional char-
acter of our data precludes causal inferences.
Conclusions
Between 2009 and 2011, the total costs for T1DM in the
Netherlands (based on reimbursement data) were more
than € 55 million, corresponding to an mean of € 8326
euros per child with T1DM per annum. Costs were high-
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Fig. 1 Mean costs (in euros) per child for the management of type 1 diabetes according to the number of patients per hospital
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the costs found in the present study seem to be higher
than in previous reports from other countries. This may
be partly explained by increased device use and differences
in healthcare systems and study methods. Given the move
towards more device-intensive and multidisciplinary care
for children with T1DM, it is likely that the health expend-
iture for T1DM will continue to rise in the coming years.
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